WO2007087420A3 - Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof - Google Patents

Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof Download PDF

Info

Publication number
WO2007087420A3
WO2007087420A3 PCT/IB2007/004164 IB2007004164W WO2007087420A3 WO 2007087420 A3 WO2007087420 A3 WO 2007087420A3 IB 2007004164 W IB2007004164 W IB 2007004164W WO 2007087420 A3 WO2007087420 A3 WO 2007087420A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycoproteins
human
glycans
produce
fungi
Prior art date
Application number
PCT/IB2007/004164
Other languages
French (fr)
Other versions
WO2007087420A9 (en
WO2007087420A2 (en
WO2007087420A8 (en
Inventor
Jan Holgersson
Anki Gustafsson
Original Assignee
Recopharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recopharma Ab filed Critical Recopharma Ab
Priority to JP2009529458A priority Critical patent/JP2009544760A/en
Priority to EP07849046A priority patent/EP2021366A2/en
Priority to AU2007208218A priority patent/AU2007208218A1/en
Priority to CA002637947A priority patent/CA2637947A1/en
Publication of WO2007087420A2 publication Critical patent/WO2007087420A2/en
Publication of WO2007087420A8 publication Critical patent/WO2007087420A8/en
Publication of WO2007087420A9 publication Critical patent/WO2007087420A9/en
Publication of WO2007087420A3 publication Critical patent/WO2007087420A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce O-glycans or other structures along human glycosylation pathways. This is achieved using a combination of engineering and/or selection of strains which: do not express certain enzymes which create the undesirable complex structures characteristic of the fungal glycoproteins, which express exogenous enzymes selected either to have optimal activity under the conditions present in the fungi where activity is desired, or which are targeted to an organelle where optimal activity is achieved, and combinations thereof wherein the genetically engineered eukaryote expresses multiple exogenous enzymes required to produce 'human-like' glycoproteins.
PCT/IB2007/004164 2006-01-23 2007-01-23 Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof WO2007087420A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009529458A JP2009544760A (en) 2006-01-23 2007-01-23 Production and use of proteins carrying oligomannose or human-like glycans in yeast
EP07849046A EP2021366A2 (en) 2006-01-23 2007-01-23 Production of proteins carrying oligomannose or human-like glycans in yeast and methods use thereof
AU2007208218A AU2007208218A1 (en) 2006-01-23 2007-01-23 Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
CA002637947A CA2637947A1 (en) 2006-01-23 2007-01-23 Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76163206P 2006-01-23 2006-01-23
US60/761,632 2006-01-23

Publications (4)

Publication Number Publication Date
WO2007087420A2 WO2007087420A2 (en) 2007-08-02
WO2007087420A8 WO2007087420A8 (en) 2008-09-25
WO2007087420A9 WO2007087420A9 (en) 2008-11-06
WO2007087420A3 true WO2007087420A3 (en) 2008-12-31

Family

ID=38309861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004164 WO2007087420A2 (en) 2006-01-23 2007-01-23 Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof

Country Status (6)

Country Link
US (1) US20070184063A1 (en)
EP (1) EP2021366A2 (en)
JP (1) JP2009544760A (en)
AU (1) AU2007208218A1 (en)
CA (1) CA2637947A1 (en)
WO (1) WO2007087420A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184063A1 (en) * 2006-01-23 2007-08-09 Jan Holgersson Production of Proteins Carrying Oligomannose or Human-Like Glycans in Yeast and Methods of Use Thereof
PL2148691T3 (en) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
EP2448955B1 (en) 2009-06-29 2015-09-30 Synthetic Genomics, Inc. Acyl-acp thioesterase genes and uses therefor
MX339809B (en) 2010-05-27 2016-06-09 Merck Sharp & Dohme Corp * Method for preparing antibodies having improved properties.
KR20140028013A (en) 2011-05-25 2014-03-07 머크 샤프 앤드 돔 코포레이션 Method for preparing fc-containing polypeptides having improved properties
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
EP2744918A4 (en) * 2011-08-17 2015-06-10 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof
CN104800838B (en) * 2015-04-14 2018-01-09 深圳市中联生物科技开发有限公司 MUC1 Fc polypeptide vaccines and its preparation method and application
CN105950647A (en) * 2016-05-16 2016-09-21 浙江理工大学 Method for efficiently expressing and preparing external-secretion-type human CA125
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177256B1 (en) * 1993-12-24 2001-01-23 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
WO2003010201A2 (en) * 2001-07-20 2003-02-06 Absorber, Ab Blood group antigen fusion polypeptides and methods of use thereof
WO2003088995A2 (en) * 2002-04-22 2003-10-30 Recopharma Ab Mucin fusion polypeptide vaccines, compositions and methods of use thereof
WO2003089450A2 (en) * 2002-04-22 2003-10-30 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
WO2007039788A1 (en) * 2004-10-14 2007-04-12 Recopharma Ab Composition and methods for inhibiting h. pylori adhesion and infection
WO2007087420A2 (en) * 2006-01-23 2007-08-02 Recopharma Ab Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3618637A (en) * 1970-02-04 1971-11-09 Deseret Pharma Rotary mixing valve
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
US7399847B1 (en) * 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
US6689605B1 (en) * 1997-05-22 2004-02-10 Uab Research Foundation Controlling immune response to specific antigens

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177256B1 (en) * 1993-12-24 2001-01-23 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
WO2003010201A2 (en) * 2001-07-20 2003-02-06 Absorber, Ab Blood group antigen fusion polypeptides and methods of use thereof
WO2003088995A2 (en) * 2002-04-22 2003-10-30 Recopharma Ab Mucin fusion polypeptide vaccines, compositions and methods of use thereof
WO2003089450A2 (en) * 2002-04-22 2003-10-30 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
WO2007039788A1 (en) * 2004-10-14 2007-04-12 Recopharma Ab Composition and methods for inhibiting h. pylori adhesion and infection
WO2007087420A2 (en) * 2006-01-23 2007-08-02 Recopharma Ab Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AEED P A ET AL: "Partial characterization of the N-linked oligosaccharide structures on P-selectin glycoprotein ligand-1 (PSGL-1).", CELL RESEARCH MAR 2001, vol. 11, no. 1, March 2001 (2001-03-01), pages 28 - 36, XP002481102, ISSN: 1001-0602 *
CHIBA A ET AL: "Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 24 JAN 1997, vol. 272, no. 4, 24 January 1997 (1997-01-24), pages 2156 - 2162, XP002481101, ISSN: 0021-9258 *
DI STASIO ENRICO ET AL: "A fast and accurate procedure to collect and analyze unfolding fluorescence signal: The case of dystroglycan domains.", BIOPHYSICAL CHEMISTRY, vol. 107, no. 2, 1 February 2004 (2004-02-01), pages 197 - 211, XP002481103, ISSN: 0301-4622 *
HAMILTON S R ET AL: "Production of complex human glycoproteins in yeast", SCIENCE, WASHINGTON, DC, vol. 301, no. 5637, 29 August 2003 (2003-08-29), pages 1244 - 1246, XP002267832, ISSN: 0036-8075 *
LAM JENNIFER S ET AL: "A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 2005, vol. 175, no. 11, 1 December 2005 (2005-12-01), pages 7496 - 7503, XP002481100, ISSN: 0022-1767 *
POWERS D B ET AL: "Expression of single-chain Fv-Fc fusions in Pichia pastoris", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 251, no. 1-2, 1 May 2001 (2001-05-01), pages 123 - 135, XP004233079, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
WO2007087420A9 (en) 2008-11-06
WO2007087420A2 (en) 2007-08-02
US20070184063A1 (en) 2007-08-09
EP2021366A2 (en) 2009-02-11
JP2009544760A (en) 2009-12-17
CA2637947A1 (en) 2007-07-23
AU2007208218A1 (en) 2007-08-02
WO2007087420A8 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2002000879A3 (en) Methods for producing modified glycoproteins
WO2007087420A8 (en) Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
WO2004074458A3 (en) N-acetylglucosaminyltransferase iii expression in lower eukaryotes
MXPA04006357A (en) Methods to engineer mammalian-type carbohydrate structures.
WO2007130638A3 (en) Production of sialylated n-glycans in lower eukaryotes
WO2004074499A3 (en) Combinatorial dna library for producing modified n-glycans in lower eukaryotes
WO2007032792A3 (en) Genetically modified yeast of the species issatchenkia orientalis and closely related species and fermentation processes using same
Lee et al. An episomal expression vector for screening mutant gene libraries in Pichia pastoris
MX2010005937A (en) Plants with modified starch metabolism.
IN2014CN02964A (en)
WO1998006835A3 (en) Modifying insect cell gylcosylation pathways with baculovirus expression vectors
CA2819071A1 (en) Fusion enzymes
WO2006096050A3 (en) Glycoengineering in mushrooms
CA2230975A1 (en) Wheat aleurone promoter
Kim et al. Development of an engineered Saccharomyces cerevisiae strain for production of a Man9GlcNAc2 glycan and glycosylated protein substrates for glycosidase and glycosyltranferase activity assays
Fraser et al. Identifying the effects of N-glycan differences between Nicotiana benthamiana and Pichia pastoris on recombinant enzymes
WO2023130078A3 (en) Genetically modified mycelium for producing psychotropic alkaloids
Gurgis et al. Using your head! Finite Element Analysis of head-first burrowing Pygopodids (Gekkota)
WO2004003208A3 (en) Stress tolerant plant
Weidanz Hexosamine metabolism in the human malaria parasite Plasmodium falciparum.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2009529458

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2637947

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007208218

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007849046

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07717023

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2007208218

Country of ref document: AU

Date of ref document: 20070123

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: JP